Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.60 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936927 | 0.92 | CA1 (0.66) | ALDH1A1HSD17B10KDM4EHPGDRAB9A | |
| SCHEMBL10084687 | 0.90 | NPC1 (0.73) | ALDH1A1HSD17B10KDM4EHPGDRAB9A | |
| SCHEMBL11901042 | 0.88 | HDAC6 (0.70) | ALDH1A1HSD17B10HPGDRAB9AMMP13 | |
| SCHEMBL4483467 | 0.88 | MMP13 (0.59) | ALDH1A1HSD17B10KDM4EHPGDMMP13 | |
| SCHEMBL14797152 | 0.86 | MMP13 (0.58) | ALDH1A1HSD17B10KDM4EHPGDRAB9A | |
| SCHEMBL14724810 | 0.86 | GAA (0.62) | ALDH1A1HSD17B10KDM4EHPGDMMP13 | |
| SCHEMBL5325191 | 0.86 | MMP13 (0.58) | ALDH1A1HSD17B10KDM4EHPGDMMP13 | |
| SCHEMBL30780038 | 0.86 | GAA (0.62) | ALDH1A1HSD17B10KDM4EHPGDMMP13 | |
| SCHEMBL22047184 | 0.85 | PPARG (0.78) | ALDH1A1HSD17B10HPGDRAB9ANPC1 | |
| SCHEMBL1684294 | 0.84 | MMP13 (0.62) | ALDH1A1HSD17B10KDM4EHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| CN-1383823-A | Methods of treating or inhibiting neutrophil chemotaxis by administering MEK inhibitors | WARNER LAMBERT CO (US) | 2002-12-11 | — | — | CN | claimed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| EP-1523473-B1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1383823-A | Methods of treating or inhibiting neutrophil chemotaxis by administering MEK inhibitors | WARNER LAMBERT CO (US) | 2002-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | ALDH1A1 2193/4885HSD17B10 2457/4885KDM4E 2606/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | ALDH1A1 2221/4885HSD17B10 3033/4885KDM4E 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.